Skye Bioscience, Inc.
Skye Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing GPCR-modulating therapies for obesity, overweight, and related conditions. Its lead program, nimacimab, is a subcutaneous injectable antibody targeting the CB1 receptor, and the company operates through a small corporate structure with subsidiaries in the United States, Australia, and Canada.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of nimacimab, a CB1-targeting antibody for obesity and related metabolic conditions.
Early-stage research on additional GPCR-modulating molecules and related assets.
Use of CROs, investigative sites, and consultants to run trials and support regulatory advancement.
Third-party manufacturing and process development for nimacimab and future biologics.
Customers
Skye Bioscience does not yet commercialize products, so its near-term counterparties are primarily clinical trial sites, contract research organizations, manufacturers, and scientific consultants rather than end-market buyers. If approved, nimacimab would be sold to physicians, obesity specialists, and healthcare systems treating patients with obesity and overweight. The company may also pursue collaboration partners that can help fund development or provide commercial infrastructure.
CROs, investigators, and trial sites that execute nimacimab studies and generate clinical data.
Third-party biologics manufacturers and consultants that support drug substance and drug product supply.
Physicians and obesity-treatment providers who would prescribe nimacimab if approved.
Pharmaceutical or biotech partners that may provide funding, development support, or commercialization reach.
Strategy
Skye Bioscience’s strategy centers on advancing nimacimab through clinical development and building evidence for its use in obesity and related metabolic conditions. The company also seeks to expand its pipeline of GPCR-based molecules while relying on third-party partners for trials, manufacturing, and eventual commercialization. This approach keeps capital focused on science and development, but it also makes execution and partner selection central to the business model.
Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
The company depends on external providers for clinical supply and trial execution.
A broader pipeline can diversify scientific risk beyond a single lead asset.
Approval would require sales, distribution, and market access capabilities.
Geography
Skye Bioscience is headquartered in San Diego, California and also maintains administrative office space in San Francisco. Its operating footprint is international at the corporate level through subsidiaries in the United States, Australia, and Canada, while clinical and manufacturing activities are largely outsourced to third parties. Because the company is pre-revenue, geography matters mainly through where it conducts research, trials, and future commercialization rather than through current sales mix.
Risks
Skye Bioscience faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, dependence on external partners, and the need for substantial additional financing before any product revenue. Its lead asset concentration means setbacks in nimacimab could materially affect the company, while competition, intellectual property protection, and regulatory requirements also remain central risks.
- Clinical development failure for nimacimabImpact: CriticalLikelihood: High
The company’s value is concentrated in a single lead program and clinical outcomes are uncertain.
Exposure: Lead obesity program
- Need for additional financingImpact: HighLikelihood: High
Development-stage biotech programs consume cash before any product revenue is generated.
Exposure: Operating runway and trial funding
- Dependence on third-party manufacturers and CROsImpact: HighLikelihood: Medium
Skye lacks internal commercial and manufacturing infrastructure, creating execution and supply risk.
Exposure: Clinical supply and trial operations
- Competition from larger biopharma companiesImpact: HighLikelihood: Medium
Competitors may have more resources, broader pipelines, and faster development capabilities.
Exposure: Obesity and metabolic disease
- Intellectual property protectionImpact: MediumLikelihood: Low
The company’s ability to defend its proprietary molecules and methods affects long-term value.
Exposure: Nimacimab and GPCR platform
Accounting
Judgemental itemsClinical trial and manufacturing costs are estimated before invoices are fully received, affecting R&D timing.
Impact: Can shift expense recognition between quarters
Prior acquisitions and licensing arrangements require valuation judgments that affect asset carrying values.
Impact: Can influence intangible asset balances and future impairment risk
The company notes estimates for litigation and related recoveries, which can be uncertain and episodic.
Impact: May create one-time gains, losses, or reserve changes
As a development-stage public company, equity awards can be a meaningful operating expense.
Impact: Affects reported G&A and R&D costs
Similar listed companies
Publicly listed companies with a comparable business focus.
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
iBio, Inc.
IBIO · Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
NovaBridge Biosciences
NBP · Pharmaceutical Preparations
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology.
Psyence Biomedical Ltd
PBMWW · Pharmaceutical Preparations
Last updated: 24/09/2026